Jump to main content
Jump to site search


Targeted and NIR light-controlled delivery of nitric oxide combined with a platinum(IV) prodrug for enhanced anticancer therapy

Author affiliations

Abstract

This study reports a strategy of combining a Pt(IV) prodrug and a ruthenium nitrosyl (Ru-NO) donor into a single nanoplatform {N-GQDs@Ru-NO-Pt@FA} in which the platinum(IV) prodrug is conjugated onto a photoactivatable NO donor (Ru-NO) through a covalent bond and the nitric oxide-releasing platinum prodrug and folate groups are decorated on N-doped graphene quantum dots (N-GQDs). After cellular uptake of the nanoplatform, the platinum(IV) prodrug was reduced to an active anti-cancer Pt(II) species inside the cancerous cells, and simultaneously, near-infrared (NIR) light illumination induced the release of NO, accompanied by a prominent photothermal effect. This nanoplatform is capable of targeting intracellular co-delivery of Pt(II) and NO under 808 nm NIR light irradiation, accompanied by photothermal therapy, thereby leading to a significant synergistic therapeutic effect.

Graphical abstract: Targeted and NIR light-controlled delivery of nitric oxide combined with a platinum(iv) prodrug for enhanced anticancer therapy

Back to tab navigation

Supplementary files

Publication details

The article was received on 18 Oct 2018, accepted on 02 Jan 2019 and first published on 03 Jan 2019


Article type: Paper
DOI: 10.1039/C8TB02743A
Citation: J. Mater. Chem. B, 2019, Advance Article

  •   Request permissions

    Targeted and NIR light-controlled delivery of nitric oxide combined with a platinum(IV) prodrug for enhanced anticancer therapy

    S. Shi, Y. Li, Q. Zhang, S. Yang and J. Liu, J. Mater. Chem. B, 2019, Advance Article , DOI: 10.1039/C8TB02743A

Search articles by author

Spotlight

Advertisements